TY - JOUR
T1 - The EHA Research Roadmap
T2 - Malignant Myeloid Diseases
AU - Döhner, Hartmut
AU - Malcovati, Luca
AU - Ossenkoppele, Gert J.
AU - Hochhaus, Andreas
AU - Maria Vannucchi, Alessandro
AU - Bullinger, Lars
AU - Cervantes, Francisco
AU - Craddock, Charles
AU - de Witte, Theo
AU - Döhner, Konstanze
AU - Dombret, Hervé
AU - Fenaux, Pierre
AU - Geissler, Jan
AU - Germing, Ulrich
AU - Guilhot, Francois
AU - Harrison, Claire
AU - Hellström-Lindberg, Eva
AU - Passamonti, Francesco
AU - Sierra, Jorge
AU - Skoda, Radek
AU - Wierzbowska, Agnieszka
N1 - Funding Information: HD received honoraria from AbbVie, Agios, Amgen, Astellas, Astex Pharmaceuticals, AstraZeneca, Berlin-Chemie, BMS, Celgene, GEMoaB, Gilead, Helsinn, Janssen, Jazz, Novartis, Oxford Biomedica, Roche, Syndax. Research grants from AbbVie, Agios, Amgen, Astellas, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Novartis, Pfizer. AH received research grants from Novartis, BMS, Pfizer, Incyte. AMV provided lectures for Novartis, BMS, AbbVie, AOP and an advisory board member for Novartis, Incyte, BMS, AOP, AbbVie, GSK. PF received research grants from BMS, Jazz, Abbvie, Janssen, Novartis. UG is Speakers horonaria from Celgene, Advice: Celgene, Institutional research support from Celgene, Novartis. LB is consulting for Abbvie, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Pfizer, and received research grants from Bayer, Jazz Pharmaceuticals, royalties of payments from Abbvie, Amgen, Astellas, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Janssen, Jazz Pharmaceuticals, Novartis, Pfizer, Sanofi, Seattle Genetics. KD is consulting for Abbvie, Lectures honoraria from BMS/Celgene, Novartis, JAZZ, Daiichi Sankyo, an advisory board member for Novartis, JAZZ, BMS/Celgene. HD received personal fees from Amgen, Celgen, Pfizer, Incyte, Novartis, Jazz Pharma, Cellectis, Immunogen, Daiichi Sankyo, Sunesis, Astellas, Janseen, Servier, Shire-Baxalta, AbbVie, Otsuka, Menarini, research grants from Amgen, Novartis, Pfizer, Jazz Pharma, Incyte, Servier. AW is in Advisory board for Abbvie, Novartis, Janssen, Pfizer, grants from Jazz Pharmaceuticals, royalties of payments from Abbvie, Novartis, Janssen, Celgene/BMS. CC is consulting for AbbVie, BMS, Novartis, Pfizer, Roche, and received grants from BMS. FC received speaker fees from Celgene and Pfizer. JG is consulting for Alnylam, Bayer, Biehringer-Ingelheim, Biomarin, Daiichi Sankyo, Gilead, Janssen, Novartis, Pfizer, Roche, Servier, Sanofi, Sobi, UCB, and received grants from Novartis, Incyte, Bristol Myers Squibb, Pfizer, Takeda. CH is consulting for CTI, Sierra, Kartos, BMS, Novartis, Keros, Galecto, and received grants from Novartis, BMS, Constellation, royalties of payments from Novartis, BMS, AOP, Roche, Jannsen. FP is an Advisory board member for Novartis, Celgene BMS, Janssen, and received the research grant from BMS. RK is an Advisory board member for Novartis and Celgen/BMS. All the other authors have no conflicts of interest to disclose. Publisher Copyright: © 2021 Wolters Kluwer Health. All rights reserved. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021
Y1 - 2021
N2 - In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 aiming to highlight achievements in the diagnostics and treatment of blood disorders, and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1-2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally a more funded future for European hematology research. The 11 EHA Research Roadmap sections include Normal Hematopoiesis; Malignant Lymphoid Diseases; Malignant Myeloid Diseases; Anemias and Related Diseases; Platelet Disorders; Blood Coagulation and Hemostatic Disorders; Transfusion Medicine; Infections in Hematology; Hematopoietic Stem Cell Transplantation; CAR-T and Other Cell-based Immune Therapies; and Gene Therapy.
AB - In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 aiming to highlight achievements in the diagnostics and treatment of blood disorders, and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1-2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally a more funded future for European hematology research. The 11 EHA Research Roadmap sections include Normal Hematopoiesis; Malignant Lymphoid Diseases; Malignant Myeloid Diseases; Anemias and Related Diseases; Platelet Disorders; Blood Coagulation and Hemostatic Disorders; Transfusion Medicine; Infections in Hematology; Hematopoietic Stem Cell Transplantation; CAR-T and Other Cell-based Immune Therapies; and Gene Therapy.
UR - http://www.scopus.com/inward/record.url?scp=85115607826&partnerID=8YFLogxK
U2 - https://doi.org/10.1097/HS9.0000000000000635
DO - https://doi.org/10.1097/HS9.0000000000000635
M3 - Review article
C2 - 34476345
SN - 2572-9241
JO - HemaSphere
JF - HemaSphere
M1 - e635
ER -